Needham analyst Serge Belanger maintained a Buy rating on Liquidia Technologies (LQDA) today and set a price target of $30.00. The company’s shares closed last Wednesday at $6.49.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -2.2% and a 35.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
Currently, the analyst consensus on Liquidia Technologies is a Moderate Buy with an average price target of $35.50, a 478.2% upside from current levels. In a report issued on April 8, Wedbush also reiterated a Buy rating on the stock with a $41.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.45 and a one-year low of $2.66. Currently, Liquidia Technologies has an average volume of 130.7K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LQDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
